Aquestive Therapeutics (AQST) Other Non-Current Assets (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Other Non-Current Assets of $2.6 million for Q1 2026, down 37.49% year-over-year from $4.2 million in Q1 2025, and little changed quarter-over-quarter from $2.6 million in Q4 2025.
Aquestive Therapeutics (AQST) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 37.49% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 37.49% YoY), while the FY2025 annual figure was $2.6 million, down 37.44% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $2.6 million, roughly flat from $2.6 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $6.9 million in Q1 2022, with the low at $2.6 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $5.4 million (2024), against an average of $4.8 million.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets decreased 5.82% in 2023, then slumped 37.49% in 2026.
- Aquestive Therapeutics' Other Non-Current Assets stood at $6.5 million in 2022, then declined by 15.7% to $5.4 million in 2023, then slipped by 22.34% to $4.2 million in 2024, then slumped by 37.44% to $2.6 million in 2025, then declined by 0.26% to $2.6 million in 2026.
- Business Quant data shows AQST's Other Non-Current Assets at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Mar 31, 2026 | 2.64 Mn |
| Dec 31, 2025 | 2.64 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Jun 30, 2025 | 3.21 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Sep 30, 2024 | 4.23 Mn |
| Jun 30, 2024 | 4.24 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Sep 30, 2023 | 5.45 Mn |
| Jun 30, 2023 | 5.47 Mn |
| Mar 31, 2023 | 6.49 Mn |
| Dec 31, 2022 | 6.45 Mn |
| Sep 30, 2022 | 5.89 Mn |
| Jun 30, 2022 | 5.90 Mn |
| Mar 31, 2022 | 6.89 Mn |
| Dec 31, 2021 | 6.90 Mn |
| Sep 30, 2021 | 6.91 Mn |